跳至主要内容
临床试验/NCT04800952
NCT04800952Unknown不适用

Pharmacokinetics of New Licensed Antibiotics in Critically Ill Patients Receiving Continuous Venovenous Haemofiltration: An International Collaborative Study

Osaka University0 个研究点目标入组 120 人开始时间: 2021年4月最近更新:
适应症

试验速览

阶段
不适用
入组人数
120
主要终点
Plasma new antibiotics concentration during continuous venovenous haemofiltration (CVVHF) in critically ill patients receiving infusion of these drugs.

研究概览

简要总结

The mortality in patients with sepsis and severe acute kidney injury requiring continuous renal replacement therapy (CRRT) remains high. Antibiotic therapy is a key treatment of these patients and in recent years new antibiotics have been licensed. However, data is lacking to determine the optimal dosing regimens of these antibiotics for high (Australia and other countries) and low intensity (Japan) of CRRT.

Aim To establish the appropriate dosing regimens of newly available antibiotics during CRRT can applied globally.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult (age ≥18 years or older)
  • Sepsis (Sepsis-3 criteria)
  • Acute kidney injury requiring CRRT (KDIGO criteria)
  • Eligible for intensive care without restrictions or limitations

排除标准

  • Chronic renal failure
  • Obvious or suspected pregnancy
  • Intracranial bleeding

结局指标

主要结局

Plasma new antibiotics concentration during continuous venovenous haemofiltration (CVVHF) in critically ill patients receiving infusion of these drugs.

时间窗: 72 hours

New drugs are Tedizolid, Daptomycin (anti-MRSA), Tazobactam/ Ceftolozane (anti-gram negative), Metronidazole (Anti-anaerobic). Plasma antibiotics concentrations will be measured at 5 time-points and prefilter and postfilter plasma and filtered-fluid antibiotics levels will be measured at 3 time-points during CVVHF.

Calculated clearances of new antibiotics during continuous venovenous haemofiltration (CVVHF) in critically ill patients receiving infusion of these drugs.

时间窗: 72 hours

New drugs are Tedizolid, Daptomycin (anti-MRSA), Tazobactam/ Ceftolozane (anti-gram negative), Metronidazole (Anti-anaerobic). Total clearance by CVVHF: (Cltotal) = (Cpre - Cpost / Cpre) × Blood flow (ml/min), Clearance by filtration: (Clfil) = (Clfil / Cpre)× replacement volume (ml/min), Clearance by absorption of the filter: (Clab) = (Cltotal) - (Clfil) (ml/min).

次要结局

  • Concentration of serum creatinine(through study completion, an average of 1 year)
  • length of stay in the hospital(up to 30 days, length of stay in the hospital will be calculated using the earliest of date that the subject is medically ready for discharge when captured, the date of discharge)
  • ICU Mortality(at ICU discharge assessed up to 30 days)
  • Hospital Mortality(at hospital discharge assessed up to 30 days)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Pharmacokinetics of Antibiotics in Critically Ill... | 临床试验